首页> 外文期刊>Current opinion in rheumatology >Interleukin-17-producing T cells in lupus.
【24h】

Interleukin-17-producing T cells in lupus.

机译:狼疮中产生白介素17的T细胞。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE OF REVIEW: Interleukin-17 (IL-17) has emerged as a key cytokine involved in the pathogenesis of autoimmune diseases. In this article, we review recently produced evidence obtained in patients and murine models of lupus that link increased IL-17 production with lupus pathology and discuss the potential roles IL-17 may play in the pathogenesis of systemic lupus erythematosus. RECENT FINDINGS: IL-17 may promote autoantibody production and IL-17-producing cells are found in afflicted organs in humans and lupus-prone mice. TH17 and CD3+CD4-CD8- cells are expanded in systemic lupus erythematosus patients and account for the increased production of IL-17. Genetic silencing of genes involved in the increased production of IL-17 in lupus-prone mice as well as treatment of mice with lupus using biologic agents that result in decreased IL-17 production leads invariably to disease mitigation. SUMMARY: The presented evidence strongly argues for the introduction of IL-17-suppressing biologics in the treatment of patients with systemic lupus erythematosus.
机译:审查的目的:白细胞介素17(IL-17)已经成为参与自身免疫性疾病发病机理的关键细胞因子。在本文中,我们回顾了最近在狼疮患者和鼠模型中获得的证据,这些证据将增加的IL-17产生与狼疮病理联系起来,并讨论了IL-17在系统性红斑狼疮发病中的潜在作用。最近的发现:IL-17可能会促进自身抗体的产生,并且在人类和狼疮易感小鼠的患病器官中发现了产生IL-17的细胞。 TH17和CD3 + CD4-CD8-细胞在系统性红斑狼疮患者中扩增,并导致IL-17产生增加。易患狼疮小鼠中IL-17产生增加的基因的遗传沉默以及使用导致IL-17产生减少的生物制剂治疗狼疮的小鼠总是导致疾病缓解。摘要:目前的证据强烈主张在系统性红斑狼疮患者的治疗中引入抑制IL-17的生物制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号